EA1181 / CompassHER2 pCR
Preoperative THP & Postoperative HP in Patients who Achieve a Pathologic Complete Response
Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2 positive breast cancer
Physician and Research Staff Educational Material
This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.
Patient Educational Material
Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material.
Study Chair Nadine Tung, MD of Beth Israel Deaconess Medical Center discusses EA1181/CompassHER2 pCR, a clinical trial that aims to optimize the amount of chemotherapy that patients with HER2-positive breast cancer receive.